摘要
Dear Editor, Significantly dysfunctional semilunar valves in the pediatric population, and especially the neonates and infants, pose a unique challenge to the congenital cardiovascular surgeon. Typically, such valves are not amenable to repair. Pediatric valve replacements, as of 2025, are fraught with a lack of acceptable prosthetic alternatives for a multitude of important reasons in younger children. A replacement valve needs to be both small enough to fit into the child’s smaller valve annulus while also accommodating rapid growth in both early childhood and the pubertal years. The other general vagaries of prosthetic valves, such as thrombus formation and infection, remain ever-present. In this milieu, emerging reports of the new field of partial heart transplant[1] provide an intriguing potential solution to these intractable problems. A partial heart transplant refers to the harvesting of only partial tissues from donors, such as the valves, and implanting them in recipients. Partial heart transplants differ from homograft implants in that they are harvested from organ donors, not cadavers, and are ethically and logistically closer to heart transplants in the aspects of retrieval, preservation, and immunosuppression to maintain living donor cells.[2] A transplanted valve that is small enough to be satisfactorily implanted yet has the potential to grow with the child is an exciting prospect, one that has the potential to change outcomes in patients with dysfunctional semilunar valves significantly. Despite the transplantation, the valve is anticipated to remain relatively unaffected by potential rejection, allowing for the use of less aggressive immunosuppressive protocols.[2] The world’s first in-human partial heart transplant was performed in 2022, in an infant with truncus arteriosus and truncal valve dysfunction, with an excellent short-term outcome.[3] Since then, the total number of such procedures has increased to more than 20. Currently, however, it is challenging to estimate the burden of significant pediatric semilunar valve dysfunction either globally or within a particular country that could theoretically benefit from partial heart transplantation. Calculation of the projected need of pediatric semilunar valve replacements is important for the following reasons: first, it will establish a sense of how many surgeons and surgical centers will be needed to develop expertise in this novel procedure, and second, it will help in planning logistical aspects relating to procurement of donor valves, policy making around such transplants within existing organ donation and ethical guidelines. Global data on the total volume of pediatric valve replacements are difficult to calculate, owing to a lack of sufficient data collection at that level. Even in a resource-rich nation such as the United States, where we currently practice, estimates of the specific pediatric incidences of critical or severe pulmonary, aortic, and truncal valve stenosis and regurgitation are not easily captured across different states and health systems. The Society of Thoracic Surgeons database,[4] while surgically comprehensive, cannot capture catheter-based balloon valvuloplasty interventions and transcatheter implantation procedures that are increasingly performed on pediatric patients. One indirect way that our group has devised to estimate the pediatric burden of dysfunctional semilunar valves – and thus – the potential volume of partial heart transplantation is via the Pediatric Health Information System database,[5] which covers approximately 50 pediatric hospitals in the United States. We queried the database for patients <18 years of age with discharge dates from January 1, 2008 to December 31, 2024, covering the past 16 years, for current procedural terminology (CPT) codes corresponding to surgical and transcatheter aortic and pulmonary valve replacement procedures. The data show that 251 procedures were performed in the 0–6-year age group, 367 procedures in the 7–12-year (prepubertal) age group, and 435 procedures in the 13–18-year age group. While prosthetic adult-size valve implants can be reasonably entertained in the oldest age group, the remaining 618 valve replacement procedures in the younger children provide an estimate of the potential partial heart transplant volume in the pediatric age group in this time frame. This would certainly represent an underestimate of the true anticipated volume and is thus a minimum number of expected procedures that would have benefited from a partial heart transplant option during that timeframe. Taken together with the plentiful estimated donor availability[6,7] of viable pediatric valves in otherwise unusable donor pediatric hearts (estimated to be ~900/year), the yet-untapped pathway of partial heart transplantation to address the problem of unrepairable pediatric semilunar valves appears to be logistically viable. This fledgling field and science would do well to be nurtured by cardiothoracic surgeons around the globe. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.